Cybrexa, Inc. is a clinical-stage oncology biotechnology company based in New Haven, CT. They are dedicated to developing an innovative class of tumor-targeting peptide drug conjugate (PDC) therapeutics that directly target the tumor microenvironment. With their alphalexTM technology platform, Cybrexa enables targeted intracellular delivery of powerful anti-cancer agents to tumor cells, offering new treatment options for cancer patients and improving their quality of life.
Founded by physician-scientists and backed by an experienced management team, Cybrexa is focused on revolutionizing cancer treatment by providing antigen-independent targeting of tumors and metastases. Their technology allows for deep tissue penetration and selective delivery of small molecule anti-cancer drugs, resulting in effective and safe therapies. With a growing pipeline of cancer therapies and a commitment to advancing their therapeutic candidates to clinical trials, Cybrexa is dedicated to making a significant impact in the field of oncology.
Generated from the website